)
Visual
test
Klaria Pharma
Klaria Pharma (KLAR) investor relations material
Klaria Pharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary20 Feb, 2026
Executive summary
Net sales increased to 9.0 MSEK for the full year 2025, up from 2.2 MSEK year-over-year, but Q4 net sales were 0 MSEK compared to 1.1 MSEK in Q4 2024.
Full-year loss after tax improved to -38.9 MSEK from -47.7 MSEK year-over-year; Q4 loss after tax was -8.4 MSEK, an improvement from -15.6 MSEK in Q4 2024.
Major milestones included the start of production and preparations for the European launch of Sumatriptan Alginate Film, and a positive patent opinion extending exclusivity to 2045.
Strategic business development accelerated with BDO to explore licensing and partnership opportunities in new markets.
Financial highlights
Net sales for 2025: 9.0 MSEK (2024: 2.2 MSEK); Q4: 0 MSEK (Q4 2024: 1.1 MSEK).
R&D expenses for 2025: 20.1 MSEK (2024: 22.1 MSEK); Q4: 4.8 MSEK (Q4 2024: 9.3 MSEK).
Profit after tax for 2025: -38.9 MSEK (2024: -47.7 MSEK); Q4: -8.4 MSEK (Q4 2024: -15.6 MSEK).
Cash flow from operating activities for 2025: -35.0 MSEK (2024: -11.9 MSEK); Q4: -2.4 MSEK (Q4 2024: 1.3 MSEK).
Cash and cash equivalents at year-end: 0.3 MSEK (2024: 0.6 MSEK).
Outlook and guidance
Initial launch of Sumatriptan Alginate Film in Germany, Spain, and Italy planned for 2026, with further European expansion in 2027.
Focus on securing additional licensing and partnership agreements in key global markets, including the US, Middle East, South America, and Asia-Pacific.
Patent protection for Sumatriptan Alginate Film expected to extend to 2045, enhancing long-term market exclusivity.
What is the strategy for 10-30% EU market share?
How will negative operating cash flow be addressed?
How does extended patent impact BDO partner search?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Klaria Pharma
- No Q3 sales, deepening losses, but key financing and European launch prep for lead product.KLAR
Q3 202526 Nov 2025 - H1 2025 saw higher sales, major financing, and preparations for a key European product launch.KLARQ2 202528 Aug 2025
- Q3 loss narrowed as Klaria pivots to licensing after EU approval for its migraine film.KLARQ3 202413 Jun 2025
- EU approval for Sumatriptan Alginate Film marks a pivotal step as Klaria seeks licensing deals.KLARQ2 202413 Jun 2025
- Q1 2025 sales surged and losses narrowed as Klaria secured a key European licensing deal.KLARQ1 20256 Jun 2025
- EU approval and licensing of Sumatriptan Alginatfilm mark a pivotal year for Klaria.KLARQ4 20245 Jun 2025
Next Klaria Pharma earnings date
Q1 202621 May, 2026
Klaria Pharma
Next Klaria Pharma earnings date
Q1 202621 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage